RT journal article
T1 Alirocumab-Associated Lichenoid Reaction: A Case Report
T2 Erupción liquenoide asociada al uso de alirocumab: presentación de un caso
A1 Román Cheuque, R.
A1 Navarro Navarro, Irene
A1 Jiménez Gallo, D.
A1 Linares Barrios, Mario Dionisio
A2 Medicina
K1 Alirocumab
K1 lichenoid eruption
AB Lichenoid eruptions (LE) pose a real diagnostic challenge dueto their clinical and histopathological similarity to lichenplanus. Inducers are varied being drug-induced lichenoideruption (DILE) a common entity, particularly in an eracharacterized by the emergence of biologic or targeted ther-apies. This is the case of an alirocumab-induced lichenoideruption, a proprotein convertase subtilisin/kexin type 9(PCSK-9) inhibitor used to treat dyslipidemia, a drug rarelyassociated with local skin adverse reactions and exception-ally with urticaria, or vasculitis.
PB Elsevier
SN 0001-7310
YR 2024
FD 2024
LK http://hdl.handle.net/10498/33757
UL http://hdl.handle.net/10498/33757
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 10-may-2026